hero image

Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017

January 17, 2017 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please note: the start time of the webcast has moved to 8:00 am ET.

Biogen Inc. (NASDAQ:BIIB) will report fourth quarter 2016 financial results on Thursday, January 26, 2017, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:00 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL.

About Biogen 
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

$Cashtags

$BIIB

thumb
May 2, 2024
Biogen Reports Progress on Corporate Responsibility Priorities

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human